ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Bioorganic & Medicinal Chemistry
Volume 16, Issue 3, 1 February 2008, Pages 1195-1205
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (680 K)

  E-mail Article   
  Add to my Quick Links   
Bookmark and share in 2collab (opens in new window)
Request permission to reuse this article
  Cited By in Scopus (0)
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bmc.2007.10.075    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2007 Elsevier Ltd All rights reserved.

Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors

Stefania Morandia, Federica Morandia, b, Emilia Casellia, Brian K. Shoichetb and Fabio Pratia, Corresponding Author Contact Information, E-mail The Corresponding Author

aDipartimento di Chimica, Università degli studi di Modena e Reggio Emilia, via Campi 183, 41100 Modena, Italy bDepartment of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, Byers Hall Room 508D, San Francisco, CA 94158, USA

Received 14 June 2007; 
revised 11 October 2007; 
accepted 23 October 2007. 
Available online 27 October 2007.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Boronic acids have proved to be promising selective inhibitors of β-lactamases, acting as transition state analogues. Starting from a previously described nanomolar inhibitor of AmpC β-lactamase, three new inhibitors were designed to gain interactions with highly conserved residues, such as Asn343, and to bind more tightly to the enzyme. Among these, one was obtained by stereoselective synthesis and succeeded in placing its anionic group into the carboxylate binding site of the enzyme, as revealed by X-ray crystallography of the complex inhibitor/AmpC. Nevertheless, it failed at improving affinity, when compared to the lead from which it was derived. The origins of this structural and energetic discrepancy are discussed.

Graphical abstract


Keywords: β-Lactamase; Inhibition; Boronic acids; X-ray crystallography

Article Outline

1. Introduction
2. Results
2.1. Design
2.2. Molecular modelling
2.3. Synthesis
2.4. Enzymology and binding affinities
2.5. X-ray crystallographic structure determination
3. Discussion
4. Experimental
4.1. Molecular modelling
4.2. Synthesis and analysis
4.2.1. General
4.3. Synthesis of (+)-pinanediol 3-(2-trityltetrazol-5-yl)phenylboronate (9)
4.4. Synthesis of (+)-pinanediol 3-(methoxycarbonylethyl)phenylboronate (10)
4.5. Synthesis of (+)-pinanediol 3-(2-methoxycarbonylvinyl)phenylboronate (11)
4.6. Synthesis of (1R)-1-(2-thiophen-2-yl-acetylamino)-1-(3-(2-carboxyvinyl)phenyl)methyl boronic acid (8)
4.7. Enzymology
4.8. Crystal growth and structure determination
4.9. Data deposition
Acknowledgements
References







Bioorganic & Medicinal Chemistry
Volume 16, Issue 3, 1 February 2008, Pages 1195-1205
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.